Sutter Bay Hospitals
Sutter Bay Hospitals was paid $52.65M by Medicaid between Jan 2018 and Dec 2024, across 207 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
CASTRO VALLEY, CA 94546
Next to other General Acute Care Hospital providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,534 | $6.62M | |
| 2019 | 102,537 | $6.64M | |
| 2020 | 79,109 | $5.10M | |
| 2021 | 84,183 | $7.02M | |
| 2022 | 89,371 | $7.46M | |
| 2023 | 112,801 | $9.92M | |
| 2024incomplete | 121,073 | $9.89M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 71,861 | 63,676 | $14.34M |
| 0450 | Emergency room services | 5.4% | 11,288 | 10,129 | $2.86M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 6,204 | 6,021 | $2.74M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.2% | 15,882 | 8,742 | $2.71M |
| 99199 | Unlisted special service, procedure or report | 4.5% | 8,575 | 7,167 | $2.36M |
| 99070 | 4.1% | 29,955 | 12,605 | $2.18M | |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 6,673 | 6,300 | $2.17M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 18,158 | 16,627 | $1.82M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.6% | 2,619 | 2,541 | $1.36M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 13,849 | 12,152 | $970K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.7% | 1,561 | 1,522 | $914K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 22,302 | 20,502 | $883K |
195 more codes
| 80053 | Comprehensive metabolic panel | 1.6% | 45,034 | $819K |
| J3490 | Unclassified drugs | 1.5% | 29,915 | $792K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 3,168 | $736K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 3,180 | $731K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 5,328 | $678K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 5,628 | $636K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 8,429 | $573K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 4,598 | $559K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,253 | $500K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 54,014 | $487K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,261 | $446K |
| 99218 | <1% | 3,083 | $434K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,033 | $404K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,245 | $341K |
| 0250 | <1% | 4,434 | $336K | |
| 82077 | <1% | 2,946 | $330K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,898 | $312K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,763 | $253K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,171 | $247K |
| 99285 | Emergency room visit (most serious) | <1% | 1,888 | $234K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,016 | $223K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,945 | $219K |
| 97139 | <1% | 5,326 | $208K | |
| 84484 | <1% | 17,658 | $197K | |
| Z7502 | <1% | 5,086 | $189K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,716 | $189K |
| 70496 | <1% | 696 | $182K | |
| 70498 | <1% | 687 | $179K | |
| 86850 | <1% | 2,754 | $166K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,657 | $165K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,928 | $164K |
| 81001 | <1% | 18,700 | $163K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,927 | $162K |
| 93971 | <1% | 941 | $155K | |
| 76801 | <1% | 1,719 | $152K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,580 | $141K |
| 99221 | <1% | 998 | $137K | |
| 83690 | <1% | 16,074 | $136K | |
| 80143 | <1% | 1,170 | $134K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,330 | $134K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 533 | $130K |
| 80179 | <1% | 1,118 | $127K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,336 | $120K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,910 | $118K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 789 | $117K |
| 86901 | <1% | 4,357 | $114K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 881 | $110K |
| 99283 | Emergency room visit (moderate) | <1% | 1,674 | $109K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,040 | $109K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 4,438 | $109K |
| 86900 | <1% | 4,615 | $98K | |
| 97750 | <1% | 1,448 | $97K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,847 | $97K |
| 85730 | <1% | 4,796 | $93K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,472 | $92K |
| 85610 | <1% | 6,232 | $91K | |
| 83880 | <1% | 2,686 | $89K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,592 | $75K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,406 | $74K |
| 73630 | <1% | 1,294 | $74K | |
| 70486 | <1% | 206 | $71K | |
| 84703 | <1% | 3,677 | $64K | |
| 73030 | <1% | 1,324 | $62K | |
| 73610 | <1% | 1,314 | $58K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,628 | $57K |
| 73562 | <1% | 1,427 | $57K | |
| 81025 | <1% | 8,783 | $49K | |
| 71250 | <1% | 250 | $49K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 95 | $49K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,647 | $48K |
| 72170 | <1% | 449 | $48K | |
| 84702 | <1% | 2,688 | $47K | |
| 82947 | <1% | 7,393 | $47K | |
| 90715 | <1% | 720 | $46K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,721 | $45K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,395 | $45K |
| 83605 | <1% | 3,619 | $42K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 30 | $41K |
| 87040 | <1% | 3,667 | $41K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 619 | $41K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 459 | $40K |
| 0762 | <1% | 45 | $40K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 792 | $39K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 442 | $37K |
| 73130 | <1% | 763 | $37K | |
| 96376 | <1% | 319 | $36K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,626 | $34K |
| 97113 | <1% | 802 | $33K | |
| 76981 | <1% | 276 | $31K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 698 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,661 | $31K |
| 83735 | <1% | 3,996 | $30K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 788 | $30K |
| J1815 | Injection, insulin, per 5 units | <1% | 849 | $30K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 982 | $30K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,831 | $27K |
| 81003 | <1% | 8,016 | $25K | |
| 74174 | <1% | 45 | $24K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,540 | $23K |
| 87186 | <1% | 2,126 | $20K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,973 | $20K |
| 87077 | <1% | 2,096 | $20K | |
| 85379 | <1% | 1,595 | $19K | |
| 82805 | <1% | 656 | $19K | |
| 87430 | <1% | 1,438 | $18K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 469 | $17K |
| 86920 | <1% | 63 | $14K | |
| 0270 | <1% | 586 | $14K | |
| 94060 | <1% | 169 | $13K | |
| 94644 | <1% | 425 | $12K | |
| 72100 | <1% | 270 | $12K | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 102 | $11K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 920 | $10K |
| 87634 | <1% | 111 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 812 | $10K |
| 87210 | <1% | 1,594 | $9K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 27 | $8K |
| 73110 | <1% | 204 | $8K | |
| 94726 | <1% | 170 | $8K | |
| 73560 | <1% | 214 | $8K | |
| 94729 | <1% | 154 | $8K | |
| 59025 | Fetal non-stress test | <1% | 174 | $8K |
| 73502 | <1% | 193 | $8K | |
| 76770 | <1% | 79 | $8K | |
| 87400 | <1% | 990 | $8K | |
| 93970 | <1% | 28 | $8K | |
| Z7610 | <1% | 662 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 189 | $5K |
| 96367 | <1% | 99 | $5K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 13 | $5K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 91 | $5K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 127 | $4K |
| 93975 | <1% | 14 | $4K | |
| 95816 | <1% | 43 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 159 | $4K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 280 | $3K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 12 | $3K |
| 72131 | <1% | 13 | $3K | |
| 73590 | <1% | 79 | $3K | |
| 73080 | <1% | 50 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,596 | $3K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 116 | $3K |
| 82550 | <1% | 302 | $2K | |
| 71020 | <1% | 63 | $2K | |
| 76870 | <1% | 27 | $2K | |
| 86140 | <1% | 282 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 61 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 84 | $2K |
| 73090 | <1% | 26 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 32 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 27 | $2K |
| 73140 | <1% | 40 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 14 | $1K |
| 84100 | <1% | 259 | $1K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 393 | $1K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 669 | $1K |
| 76536 | <1% | 14 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 104 | $1K |
| 71010 | <1% | 53 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 71 | $1K |
| 97799 | <1% | 39 | $1K | |
| 87081 | <1% | 96 | $1K | |
| 72040 | <1% | 24 | $972.10 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 43 | $842.24 |
| 85651 | <1% | 269 | $823.63 | |
| 80061 | Lipid panel | <1% | 69 | $787.54 |
| 80076 | <1% | 72 | $773.76 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 101 | $763.32 |
| 93017 | <1% | 12 | $748.34 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 26 | $737.06 |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 20 | $662.34 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 26 | $635.31 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 33 | $625.12 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 22 | $607.14 |
| S0028 | Injection, famotidine, 20 mg | <1% | 20 | $566.35 |
| 73552 | <1% | 12 | $547.97 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 64 | $524.39 |
| 87420 | <1% | 61 | $400.31 | |
| 87899 | <1% | 41 | $376.26 | |
| 74018 | <1% | 12 | $302.46 | |
| 80047 | <1% | 27 | $267.51 | |
| 85027 | <1% | 29 | $206.93 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 43 | $189.04 |
| 84145 | <1% | 12 | $175.00 | |
| 82010 | <1% | 15 | $163.28 | |
| 86592 | <1% | 24 | $144.43 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 20 | $137.21 |
| 87088 | <1% | 13 | $105.59 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $100.10 |
| 84439 | <1% | 12 | $99.76 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 71 | $74.83 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 91 | $56.44 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 84 | $43.19 |
| 0250R | 0% | 228 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Sutter Bay Hospitals | Oakland, CA | $46.80M |
| Sutter Bay Hospitals | Berkeley, CA | $43.78M |
| Sutter Bay Hospitals | Lakeport, CA | $39.50M |
| Sutter Bay Hospitals | Santa Rosa, CA | $35.23M |
| Sutter Bay Hospitals | Antioch, CA | $29.48M |
| Sutter Bay Hospitals | San Francisco, CA | $19.99M |
| Sutter Bay Hospitals | Burlingame, CA | $17.15M |
| Sutter Bay Hospitals | San Francisco, CA | $14.94M |
| Sutter Bay Hospitals | Novato, CA | $11.12M |
| Sutter Bay Hospitals | San Francisco, CA | $6.79M |
| Sutter Bay Hospitals | Lakeport, CA | $3.99M |
| Sutter East Bay Hospitals | Antioch, CA | $3.45M |
| Sutter Bay Hospitals | Burlingame, CA | $1.98M |
| Sutter Bay Hospitals | Lakeport, CA | $1.72M |
| Sutter East Bay Hospitals | Oakland, CA | $1.10M |
| Sutter Bay Hospitals | San Francisco, CA | $1.08M |
| Sutter East Bay Hospitals | Berkeley, CA | $946K |
| Sutter West Bay Hospitals | San Francisco, CA | $186K |
| Magnetic Imaging Affiliates, LLC | Oakland, CA | $112K |
| Sutter Bay Hospitals | Berkeley, CA | $45K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.